中源協和(600645.SH):擬增資中源濟生公司
格隆匯11月8日丨中源協和(600645.SH)公佈,中源濟生公司為公司控股子公司,公司及子公司濟生投資公司共認繳出資3,250萬元,合計持股比例為65%,關聯方上海延藜生物技術有限公司認繳出資1,750萬元,持股比例為35%。根據目標公司業務發展的需要,公司擬向目標公司增資人民幣2,000萬元,認繳目標公司新增註冊資本人民幣2,000萬元,增資完成後公司持股比例變為64.29%,公司及子公司濟生投資公司合計持股比例變為75%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.